Published in Retrovirology on June 02, 2009
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog (2014) 2.10
Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS (2011) 2.00
The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit. Curr Opin HIV AIDS (2011) 1.67
New developments in anti-malarial target candidate and product profiles. Malar J (2017) 1.50
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem (2011) 1.45
HIV latency and integration site placement in five cell-based models. Retrovirology (2013) 1.42
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med (2011) 1.30
Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res (2011) 1.23
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A (2012) 1.19
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology (2010) 1.13
T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J Mol Biol (2011) 1.12
Global Promoter Targeting of a Conserved Lysine Deacetylase for Transcriptional Shutoff during Quiescence Entry. Mol Cell (2015) 1.04
The ubiquitin ligase Siah1 controls ELL2 stability and formation of super elongation complexes to modulate gene transcription. Mol Cell (2012) 1.03
Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One (2014) 0.99
Eradication therapies for HIV Infection: time to begin again. AIDS Res Hum Retroviruses (2011) 0.99
Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis (2013) 0.99
Epigenetic control of HIV-1 post integration latency: implications for therapy. Clin Epigenetics (2015) 0.98
Cell line-dependent variability in HIV activation employing DNMT inhibitors. Virol J (2010) 0.98
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol (2012) 0.95
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) (2010) 0.94
Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One (2014) 0.92
Insights into cellular factors that regulate HIV-1 replication in human cells. Biochemistry (2011) 0.92
Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother (2014) 0.92
A cure for AIDS: a matter of timing? Retrovirology (2013) 0.92
Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. J Virol (2015) 0.90
The macrophage: a therapeutic target in HIV-1 infection. Mol Cell Ther (2014) 0.90
Molecular Understanding of HIV-1 Latency. Adv Virol (2012) 0.90
Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology (2013) 0.89
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad (2015) 0.87
Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells. J Antimicrob Chemother (2013) 0.85
The Environmental Pollutant Cadmium Promotes Influenza Virus Replication in MDCK Cells by Altering Their Redox State. Int J Mol Sci (2013) 0.84
Measuring glutathione redox potential of HIV-1-infected macrophages. J Biol Chem (2014) 0.84
Therapy for persistent HIV. Trends Pharmacol Sci (2010) 0.82
Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB. PLoS One (2012) 0.81
Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy. PLoS One (2014) 0.80
Therapeutic imprinting of the immune system: towards a remission of AIDS in primates? Retrovirology (2012) 0.79
Dual targeting of the thioredoxin and glutathione systems in cancer and HIV. J Clin Invest (2016) 0.78
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. Antimicrob Agents Chemother (2015) 0.78
Interaction between endogenous bacterial flora and latent HIV infection. Clin Vaccine Immunol (2013) 0.77
Human CD4+ T cells require exogenous cystine for glutathione and DNA synthesis. Oncotarget (2015) 0.77
Deployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic development. J Gen Virol (2012) 0.77
World AIDS Day: together we will stop HIV transmission and conquer AIDS. Retrovirology (2013) 0.75
Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies. AIDS Res Ther (2012) 0.75
The 20th International AIDS Conference: where do we go from here? J Int AIDS Soc (2014) 0.75
We all need to know about HIV cure research: a case report. J Virus Erad (2015) 0.75
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27
The challenge of finding a cure for HIV infection. Science (2009) 8.41
HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J (2003) 6.11
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res (2007) 4.91
Class II histone deacetylases: versatile regulators. Trends Genet (2003) 4.63
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J (2008) 3.86
Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact (1998) 2.55
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS (2002) 2.40
A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol (2009) 2.30
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol (2004) 2.23
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Transcriptional repression of human immunodeficiency virus type 1 by AP-4. J Biol Chem (2006) 1.73
Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol (2009) 1.55
In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology (2007) 1.55
Regulation of HIV-1 latency by T-cell activation. Cytokine (2007) 1.48
Oxidative stress in human immunodeficiency virus infection. Cell Mol Life Sci (1997) 1.34
Iron metabolism and HIV infection: reciprocal interactions with potentially harmful consequences? Cell Biochem Funct (1999) 1.32
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol (2008) 1.21
HIV-1 latency in actively dividing human T cell lines. Retrovirology (2008) 1.16
Can HIV be Cured? Mechanisms of HIV persistence and strategies to combat it. Curr HIV Res (2004) 1.13
Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol (2004) 1.08
A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma. J Pharm Biomed Anal (2006) 1.07
Genetic and metabolic control of the mitochondrial transmembrane potential and reactive oxygen intermediate production in HIV disease. Antioxid Redox Signal (2000) 1.02
Intracellular GSH content and HIV replication in human macrophages. J Leukoc Biol (1997) 0.99
GSH and analogs in antiviral therapy. Mol Aspects Med (2008) 0.98
Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology (2005) 0.96
The therapeutic uses of chromatin-modifying agents. Expert Opin Ther Targets (2007) 0.96
Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology (2007) 0.95
Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies. Curr Top Med Chem (2009) 0.91
Valproic acid reduces the intracellular level of glutathione and stimulates human immunodeficiency virus. Chem Biol Interact (1994) 0.90
HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA. Biochem Pharmacol (2007) 0.84
Oxidative stress response and signaling in hematological malignancies and HIV infection. Int J Hematol (2000) 0.83
Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg Med Chem Lett (2005) 0.79
Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. Drug Metab Dispos (1995) 0.78
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell (2010) 2.89
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2004) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell (2010) 2.50
Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell (2013) 2.32
Butyrophilin 3A1 binds phosphorylated antigens and stimulates human γδ T cells. Nat Immunol (2013) 1.95
Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov (2007) 1.91
Functional deficit of T regulatory cells in Fulani, an ethnic group with low susceptibility to Plasmodium falciparum malaria. Proc Natl Acad Sci U S A (2008) 1.86
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc (2010) 1.61
Bcl-2 Phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J Biol Chem (2006) 1.60
Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res (2002) 1.57
Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem (2005) 1.51
Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer (2011) 1.47
Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev (2005) 1.46
Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep (2009) 1.39
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
Inhibition of influenza A virus replication by resveratrol. J Infect Dis (2005) 1.33
Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene (2005) 1.30
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog (2012) 1.26
Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med (2004) 1.25
Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int J Mol Sci (2013) 1.25
Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ Res (2007) 1.24
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res (2006) 1.22
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue. Diabetes (2012) 1.22
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol (2008) 1.21
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A (2012) 1.19
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood (2013) 1.19
Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells (2014) 1.19
Trials with 'epigenetic' drugs: an update. Mol Oncol (2012) 1.19
Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood (2006) 1.18
Sirtuins and disease: the road ahead. Front Pharmacol (2012) 1.15
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem (2008) 1.13
Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology (2010) 1.13
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS (2006) 1.12
Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans. Antimicrob Agents Chemother (2008) 1.11
Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation. J Biol Chem (2010) 1.11
Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem (2005) 1.10
Up-regulation of pro-inflammatory genes as adaptation to hypoxia in MCF-7 cells and in human mammary invasive carcinoma microenvironment. Cancer Sci (2010) 1.10
Nε-lysine acetylation determines dissociation from GAP junctions and lateralization of connexin 43 in normal and dystrophic heart. Proc Natl Acad Sci U S A (2011) 1.09
Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues. Epigenetics (2012) 1.08
Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome. PLoS One (2010) 1.08
Bispyridinium dienes: histone deacetylase inhibitors with selective activities. J Med Chem (2007) 1.08
Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication. J Biol Chem (2009) 1.07
Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2. FASEB J (2003) 1.07
Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res (2008) 1.07
Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. J Cell Physiol (2004) 1.06
Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480. Bioorg Med Chem Lett (2004) 1.06
Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS (2011) 1.06
Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol J (2007) 1.06
Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood (2004) 1.06
Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9. Diabetes (2011) 1.04
Infectious agents and neurodegeneration. Mol Neurobiol (2012) 1.03
Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J Med Chem (2006) 1.03
γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol (2011) 1.03
Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia. Blood (2012) 1.02
Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem (2006) 1.02
HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim Biophys Acta (2008) 1.02
Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorg Med Chem Lett (2006) 1.02
Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol Res (2010) 1.02
An analog of BIX-01294 selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases. J Mol Biol (2011) 1.01
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. Cardiovasc Res (2010) 1.01
Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. Clin Colorectal Cancer (2009) 1.00
Antimalarial and antileishmanial activities of aroyl-pyrrolyl-hydroxyamides, a new class of histone deacetylase inhibitors. Antimicrob Agents Chemother (2004) 0.99
Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des (2009) 0.99